Recognizing a Pioneer in Alzheimer's Research
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has announced that its founder, Professor Lars Lannfelt, will be honored with the 2025 Hartwig Piepenbrock-DZNE Prize. This significant accolade is awarded for his pivotal contributions to understanding Alzheimer's disease and the development of the breakthrough drug lecanemab. The German Center for Neurodegenerative Diseases (DZNE) and the Piepenbrock Group present this award, reflecting the importance of Professor Lannfelt's work in the field of Alzheimer's research.
A Messagge of Hope
Upon receiving the award, Professor Lannfelt expressed immense pride, saying, "Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life." Lannfelt highlighted the recent advancements in Alzheimer's treatments, triumphantly noting the benefits highlighted in Phase 3 Clarity AD trial results. His optimism underscores a critical shift in how researchers approach Alzheimer's treatment, with lecanemab emerging as a potential game-changer that could not only slow down disease progression but might eventually halt its trajectory.
The Journey of Discovery
In 2003, Professor Lars Lannfelt founded BioArctic alongside Pär Gellerfors, with the goal of creating innovative antibody treatments inspired by Lannfelt’s groundbreaking research on amyloid-beta protein. This pivotal work laid the foundation for lecanemab, a collaborative effort with the Japanese pharmaceutical company Eisai. By targeting specific forms of amyloid-beta that contribute to Alzheimer’s disease, lecanemab facilitates the removal of these proteins from the brain, offering new hope for patients and caregivers alike.
A Testament to Research Excellence
The Hartwig Piepenbrock-DZNE Prize has been awarded biennially since 2011, recognizing remarkable research efforts in the area of neurodegenerative disorders. It serves as a tribute to Hartwig Piepenbrock, the former CEO of the Piepenbrock Group, who left a left a legacy of dedication to tackling dementia. Winners of the prize are selected by an esteemed international committee coordinated by DZNE, and this award will mark its eighth presentation.
Company Overview
BioArctic AB is a Swedish biopharmaceutical innovator focused on developing advanced treatments for neurodegenerative diseases. The company is the originator of Leqembi (lecanemab), recognized as the first drug capable of slowing the progression of early Alzheimer's, developed in collaboration with Eisai. BioArctic is committed to addressing a range of conditions, including Alzheimer's, Parkinson's disease, ALS, and enzyme deficiency diseases, utilizing the proprietary BrainTransporter technology to enhance drug delivery to the brain. This commitment is reflected in their robust research pipeline, positioning them as leaders in the fight against neurodegenerative diseases.
Frequently Asked Questions
What is the Hartwig Piepenbrock-DZNE Prize?
The Hartwig Piepenbrock-DZNE Prize honors outstanding research in neurodegenerative disorders, promoting advancements in Alzheimer’s and related diseases.
Who is Professor Lars Lannfelt?
Lars Lannfelt is the founder of BioArctic and a notable researcher in Alzheimer's disease, celebrated for his contributions and development of lecanemab.
What is lecanemab?
Lecanemab is an antibody treatment designed to target amyloid-beta proteins, aiming to slow the progression of Alzheimer's disease.
When was BioArctic founded?
BioArctic was founded in 2003 by Lars Lannfelt and Pär Gellerfors to innovate treatments for Alzheimer's disease.
What does BioArctic focus on?
BioArctic specializes in research-based biopharmaceuticals, particularly targeting neurodegenerative diseases like Alzheimer’s and Parkinson’s.
